Business ❯Competition ❯Market Dynamics ❯Pharmaceutical Industry

Eli Lilly

FDA Expands Wegovy to Treat MASH as Novo Nordisk Halves Uninsured Ozempic Price

The targeted price cut focuses on uninsured patients to counter mounting competitive pressure.

Wegovy Wins FDA Nod for MASH as Novo Rolls Out $499 Cash Ozempic in U.S.

Novo Nordisk CEO Steps Down Following Market Challenges